Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study
Date
2020Author
Bani-Sadr, Firouze
Hentzien, Maxime
Pascard, Madeline
N’guyen, Yohan
Servettaz, Amelie
Andreoletti, Laurent
Kanagaratnam, Lukshe
Jolly, Damien
Metadata
Show full item record
Documentos PDF
Imagenes y Videos
Abstract
Background: Anti-inflammatory drugs such as corticosteroids may beneficially modulate the
host inflammatory response to CoVID-19 pneumonia.
Aims: To evaluate the impact of addition of corticosteroids to the hospital protocol for
treatment of suspected or confirmed CoVID-19 pneumonia on rates of death or intensive
care unit (ICU) admission.
Methods: A before-after study was performed to evaluate the effect of addition of corticosteroids
to our institution's COVID-19 treatment protocol on hospital mortality.
Results: Between March 3rd and April 14th 2020, 257 patients with CoVID-19 diagnosis were
included. As corticosteroids were wide used since 27 March 2020, two periods were
considered for the purposes of our study: the before period from March 3rd to 20th (n= 85)
and the “after period” (n=172) from March 26th to April 14th 2020.
The “after” period was associated with a lower risk of death (HR 0.47; 95% CI, 0.23 - 0.97;
p=0.04), and a lower risk of intensive care admission or death before ICU admission (HR 0.37
95% CI 0.21 - 0.64; p=0.0005) by multivariate analysis adjusted for age, National Early
Warning score and institutionalization status.
Conclusions: In the “after period”, the addition of corticosteroids to our institution's CoVID-19
treatment protocol was associated with a significant reduction in hospital mortality
Link to resource
https://doi.org/10.1016/j.ijantimicag.2020.106077Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.